Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments ...

Wells Fargo’s analyst, Mohit Bansal ... 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc.

Deciphering Analyst Ratings: An In-Depth Analysis A clear picture of Regeneron Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions.

JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals ... One investment analyst has rated the stock with a sell rating, six have issued a hold rating ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc.

This comprehensive analysis examines Regeneron's current position, future prospects, and the factors that could shape its performance in the coming years. Regeneron has demonstrated strong ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.Despite the decrease, the firm ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.Despite the decrease, the firm ...